Bone morbidity in chronic myeloproliferative neoplasms.

about

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera.

P2860

Q26775996-E4EF3645-EA9B-4F5C-B367-8D2E0CC9C073 Q40544293-1D06F4A9-4240-471F-A5FE-B4100FA1C4B7

P2860

Bone morbidity in chronic myeloproliferative neoplasms.

Item

http://www.wikidata.org/entity/Q38513219

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Bone morbidity in chronic myeloproliferative neoplasms.

@en

type

Item

label

Bone morbidity in chronic myeloproliferative neoplasms.

@en

prefLabel

Bone morbidity in chronic myeloproliferative neoplasms.

@en

P1476

Bone morbidity in chronic myeloproliferative neoplasms.

@en

P2093

Anne Pernille Hermann

http://www.w3.org/2001/XMLSchema#string

Hanne Vestergaard

http://www.w3.org/2001/XMLSchema#string

Lukas Frans Ocias

http://www.w3.org/2001/XMLSchema#string

Sarah Farmer

http://www.w3.org/2001/XMLSchema#string

Sigurd Broesby-Olsen

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of low-dose aspirin in polycythemia vera

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

Fracture risk associated with the use of morphine and opiates

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

P304

447-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1586/17474086.2015.1053456

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Henrik Frederiksen

P577

2015-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26036168

http://www.w3.org/2001/XMLSchema#string

Bone morbidity in chronic myeloproliferative neoplasms.

about

P2860

P2860

Bone morbidity in chronic myeloproliferative neoplasms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698